TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA PREBIOTICS FOR INFANT FORMULA MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 DBMR MARKET POSITION GRID
2.7 MULTIVARIATE MODELING
2.8 PRODUCT TIMELINE CURVE
2.9 SECONDARY SOURCES
2.10 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 EVOLUTION
5.1 EVOLUTION OF INFANT FORMULA
5.2 EVOLUTION OF PREBIOTICS FORMULA
6 REGULATIONS & QUALITY REQUIREMENTS
6.1 REGULATIONS
6.1.1 FDA
6.1.1.1 GRAS NOTICE NO. GRN 000849
6.1.1.2 GRAS NOTICE NO. GRN 00859
6.1.1.3 GRAS NOTICE NO. GRN 000797
6.1.1.4 GRAS NOTICE NO. GRN 000766
6.1.1.5 GRAS NOTICE NO. GRN 000749
6.1.1.6 GRAS NOTICE NO. GRN 000735
6.1.1.7 GRAS NOTICE NO. GRN 000729
6.1.1.8 GRAS NOTICE NO. GRN 000717
6.1.1.9 GRAS NOTICE NO. GRN 000721
6.1.1.10 GRAS NOTICE NO. GRN 000659
6.1.1.11 GRAS NOTICE NO. GRN 000650
6.1.1.12 GRAS NOTICE NO. GRN 000623
6.1.1.13 GRAS NOTICE NO. GRN 000620
6.1.2 EUROPEAN UNION
6.1.2.1 COMMISSION DIRECTIVE 2006/141/EC
6.1.3 AUSTRALIA NEW ZEALAND FOOD STANDARDS CODE
6.1.3.1 STANDARD 2.9.1
6.1.3.2 STANDARD 2.9.2
6.1.3.3 STANDARD 2.9.3
6.2 QUALITY REQUIREMENTS
7 CLINICAL TRIALS
7.1 NCT03994315
7.2 NCT03884309
7.3 NCT02594683
7.4 NCT03661736
7.5 NCT03666572
7.6 NCT03866837
7.7 NCT03476889
8 INFANT FORMULA BRAND ANALYSTS
8.1 ABBOTT
8.2 MEAD JOHNSON & COMPANY, LLC
8.3 DANONE NUTRICIA
8.4 NESTLE
8.5 PERRIGO NUTRITIONALS
8.6 HOCHDORF HOLDING AG
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 RISING NUMBER FROM PRETERM/PREMATURE BABIES
9.1.2 INCREASED RESEARCH INITIATIVE FOR NEW PRODUCT DEVELOPMENT
9.1.3 HEALTH BENEFITS ASSOCIATED WITH PREBIOTICS
9.1.4 GROWING CONCERN AND DEMAND FOR THE HEALTHY BABY FOOD
9.1.5 RISING POPULATION OF INFANT
9.2 RESTRAINTS
9.2.1 STRINGENT REGULATION AND APPROVAL CRITERIA SET BY GOVERNMENTS
9.2.2 RISING AWARENESS TOWARDS MOTHER FEEDING FOR INFANT
?
9.3 OPPORTUNITIES
9.3.1 RAPID DEVELOPMENT IN CHICORY ROOT BASED PREBIOTICS
9.3.2 EMERGING DEMAND IN DEVELOPING NATIONS
9.3.3 STRENGTHENING TRADE RELATIONSHIP BETWEEN DIFFERENT NATIONS
9.4 CHALLENGE
9.4.1 RISING NUMBER OF PRODUCT RECALLS FOR INFANT FORMULA DUE TO CONTAMINATION
10 NORTH AMERICA PREBIOTICS FOR INFANT FORMULA MARKET, BY TYPE
10.1 OVERVIEW
10.2 HUMAN MILK OLIGOSACCHARIDES (HMOS)
10.2.1 FUCOSYLLACTOSE
10.2.1.1 NEUTRAL FUCOSYLATE OLIGOSACCHARIDES
10.2.1.2 NON-FUCOSYLATED OLIGOSACCHARIDES
10.2.2 LACTO-N- TETRAOSE (LNT) & LACTO-N-NEOTETRAOSE (LNNT)
10.2.3 SIALYLLACTOSE
10.3 FRUCTOOLIGOSACCHARIDES (FOS)
10.3.1 LONG CHAIN FOS (LCFOS)
10.3.2 SINGLE CHAIN FOS (SCFOS)
10.4 GALACTOOLIGOSACCHARIDES (GOS)
10.4.1 LACTOSE DERIVED
10.4.2 GALACTOSE DERIVED
10.5 INULIN
10.6 POLYDEXTROSE (PDX)
10.7 MANNAN-OLIGOSACCHARIDES (MOS)
10.8 LACTULOSE (LOS)
11 NORTH AMERICA PREBIOTICS FOR INFANT FORMULA MARKET, BY SOURCE
11.1 OVERVIEW
11.2 PLANTS & VEGETABLES
11.2.1 WHEAT
11.2.2 CHICORY ROOT
11.2.3 BANANAS
11.2.4 LEEKS
11.2.5 TOMATOES
11.2.6 OTHERS
11.3 BACTERIA
11.4 FUNGI
11.5 ALGAE
11.6 OTHERS
?
12 NORTH AMERICA PREBIOTICS FOR INFANT FORMULA MARKET, BY GRADE
12.1 OVERVIEW
12.2 INORGANIC
12.3 ORGANIC
13 NORTH AMERICA PREBIOTICS FOR INFANT FORMULA MARKET, BY FORM
13.1 OVERVIEW
13.2 POWDER
13.3 LIQUID
14 NORTH AMERICA PREBIOTICS FOR INFANT FORMULA MARKET, BY PRODUCT TYPE
14.1 OVERVIEW
14.2 STANDARD FORMULA
14.3 SPECIAL FORMULA
14.4 FOLLOW UP FORMULA
14.5 TODDLER FORMULA
15 NORTH AMERICA PREBIOTICS FOR INFANT FORMULA MARKET, BY INFANT AGE
15.1 OVERVIEW
15.2 6-12 MONTHS
15.3 0-6 MONTHS
15.4 1-3 YEARS
16 NORTH AMERICA PREBIOTICS FOR INFANT FORMULA MARKET, BY GEOGRAPHY
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA PREBIOTICS FOR INFANT FORMULA MARKET, COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 COMPANY PROFILE
18.1 ROYAL FRIESLANDCAMPINA N.V.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 CARGILL, INCORPORATED.
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENT
18.3 INGREDION INCORPORATED
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.4 BENEO (A SUBSIDIARY OF SuDZUCKER)
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 FONTERRA CO-OPERATIVE GROUP
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENTS
18.6 BIOSYNTH CARBOSYNTH
18.6.1 COMPANY SNAPSHOT
18.6.2 PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENTS
18.7 COSUCRA
18.7.1 COMPANY SNAPSHOT
18.7.2 PRODUCT PORTFOLIO
18.7.3 RECENT DEVELOPMENTS
18.8 DANA DAIRY GROUP
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENTS
18.9 DEXTRA LABORATORIES LIMITED
18.9.1 COMPANY SNAPSHOT
18.9.2 PRODUCT PORTFOLIO
18.9.3 RECENT DEVELOPMENT
18.10 DUPONT.
18.10.1 COMPANY SNAPSHOT
18.10.2 REVENUE ANALYSIS
18.10.3 PRODUCT PORTFOLIO
18.10.4 RECENT DEVELOPMENTS
18.11 ELICITYL SA
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENT
18.12 GLYCOM A/S
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENT
18.13 GLYCOSYN LLC.
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENTS
18.14 JENNEWEIN BIOTECHNOLOGIE GMBH
18.14.1 COMPANY SNAPSHOT
18.14.2 PRODUCT PORTFOLIO
18.14.3 RECENT DEVELOPMENTS
18.15 NEW FRANCISCO (YUNFU CITY) BIOTECHNOLOGY CORPORATION LIMITED
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENTS
18.16 ROYAL COSUN
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 APPLICATION PORTFOLIO
18.16.4 RECENT DEVELOPMENT
18.17 TEREOS
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 PRODUCT PORTFOLIO
18.17.4 RECENT DEVELOPMENT
18.18 ZUCHEM INC.
18.18.1 COMPANY SNAPSHOT
18.18.2 PRODUCT PORTFOLIO
18.18.3 RECENT DEVELOPMENT
?
19 QUESTIONNAIRE
20 RELATED REPORTS